Fatal Complication of Stem Cell Transplants Gets Its First FDA-Approved Therapy

Omeros’s complement system drug Yartemlea is now FDA approved for treating a severe and potentially fatal complication of hematopoietic stem cell transplants. Our recap of other regulatory actions includes drug approvals in cancer, rare disease, and metabolic disorders. The post Fatal Complication of Stem Cell Transplants Gets Its First FDA-Approved Therapy appeared first on MedCity…

Read More

You’re Not Going to Automate MY Job

By KIM BELLARD Earlier this month U.S. dockworkers struck, for the first time in decades. Their union, the International Longshoremen’s Association (ILW), was demanding a 77% pay increase, rejecting an offer of a 50% pay increase from the shipping companies. People worried about the impact on the economy, how it might impact the upcoming election,…

Read More

Impact of Private Equity on Dentists

From a recent paper by Nasseh et al. 2026 in Health Services Research: Following acquisition, private equity-owned dental offices increased charges for dental care services by 3.3% (95% CI: 2.3%–4.4%), although allowed prices for these services remained statistically unchanged. Dental offices acquired by private equity firms tended to shift from diagnostic and preventive procedures to…

Read More